Bioxytran, Inc.
BIXT
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.26M
Close$
$-0.01
135.4% downside
Current Fair Value
135.4% downsideOvervalued by 135.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.26 Million |
|---|---|
| Enterprise Value | $2.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 1.88 |
| Outstanding Shares | 114,355,933 |
Return
| Return on Equity | 70.71% |
|---|---|
| Return on Assets | -1047.95% |
| Return on Invested Capital | 64.93% |
Valuation & Multiples
| P/E Ratio | -0.71 |
|---|---|
| PEG | 0.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioxytran, Inc.
2 employees
CEO: David Platt Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT...